Overview

Bioequivalence Study of Perampanel Tablets 10 mg

Status:
COMPLETED
Trial end date:
2024-02-06
Target enrollment:
Participant gender:
Summary
An open-label, balanced, randomized, two treatment, two sequence, two period, two way cross-over, single dose bioequivalence study of Perampanel Tablets 10 mg of Humanis Sağlık A.ġ., Turkey and Fycompa 10 mg film-coated tablets of Eisai GmbH Edmund-Rumpler-Straße 3 60549 Frankfurt am Main Deutschland in normal, healthy, adult, human subjects under fasting condition.
Phase:
PHASE1
Details
Lead Sponsor:
Humanis Saglık Anonim Sirketi
Treatments:
perampanel
Tablets